Optimizing the Use of Novel Agents for the Treatment of Leukemia. 

A series of Live Grand Rounds Presentations and an on-demand CME-certified Webcourse

Welcome to "Optimizing the Use of Novel Agents for the Treatment of Leukemia.” A series of live CME-certified in-hospital presentations will be held at locations nationwide in 2018 and an online CME-certified webcourse is also available.

PROGRAM OVERVIEW/STATEMENT OF NEED
There have been several significant advances related to the treatments of CML, AML, and ALL. Innovative therapies that are recently FDA approved or in the later stages of clinical development are revolutionizing options for effective care in these patients. These rapid advancements and novel therapeutic options for multiple hematologic malignancies require clinicians to have a heightened awareness in order to optimize the management of leukemia and improve patient outcomes.

Optimizing the Use of Novel Agents for the Treatment of Leukemia will guide clinicians in the integration of new data into clinical practice through case-based discussions and an emphasis on the importance of patient communication. This educational initiative is designed to increase awareness of novel treatment options and, ultimately, allow clinicians to appropriately incorporate new data into the management of their leukemia patients.

TARGET AUDIENCE
This activity is intended for community-based hematologists/oncologists and other clinicians involved in the care of patients with leukemia.

EDUCATIONAL OBJECTIVES
This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Increase awareness of the importance of long-term safety with BCR-ABL TKIs in CML management for individualized treatment based on patient history and any comorbidities
  • Improve awareness of FDA-approved agents and/or therapies under development for the treatment of AML and ALL
  • Incorporate FDA-approved agents and therapies under development into treatment paradigms for AML and ALL

ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

For information about the accreditation of this activity, please email: contact@potomacme.org

CREDIT DESIGNATION
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FEE AND RECEIVING CME/CE CREDIT
There is no fee for this educational activity. To receive CME/CE credit the participant must:

  • Participate in this one-hour-long program;
  • Sign in on the sheet provided by the host coordinator;
  • Complete the evaluation forms; 
  • Return the evaluation forms to the host coordinator.

AGENDA

  • Welcome and Introductions
  • Chronic Myeloid Leukemia
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Q&A Session and Activity Roundup

DISCLOSURE INFORMATION
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

LIVE PROGRAM SCHEDULE
​If you are interested in attending or scheduling a meeting in your local area, please contact Kathy Whyte at 443-909-7901 or kwhyte@rockpointe.com 

RELATED ONLINE OFFERINGS
Click here to access the CME-certified webcourse associated with this program.

LIVE PROGRAM MATERIALS FOR SPEAKERS AND ADMINISTRATORS

I. Administrator Material

Program Poster (PDF)
Program Flyer (PDF)
Program Syllabus (PDF)
Slide Handout – black & white (PDF)

II. Speaker Material

Thank you for joining us as an expert speaker for the grand rounds series, "Optimizing the Use of Novel Agents for the Treatment of Leukemia."

This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions.

Transcript of Speaker Orientation Download (PDF)

Audio download of Speaker Orientation (MP3)

CME-certified Program Slides that have been reviewed and approved and are to be used for this activity.

STEERING COMMITTEE

 B. DOUGLAS SMITH, MD
 Professor of Oncology
 Johns Hopkins University, School of Medicine
 Baltimore, MD


 


B. Douglas Smith, MD received his medical degree from the Medical College of Pennsylvania in Philadelphia, PA, followed by an internship, residency, and chief residency in internal medicine at the University of Rochester’s Strong Memorial Hospital. Dr. Smith went on to complete his oncology fellowship at the Johns Hopkins University School of Medicine in Baltimore, MD, where he joined the faculty at Johns Hopkins and is now Professor of Oncology in the Division of Hematologic Malignancies.

Dr. Smith’s research focuses on taking new and promising laboratory insights and developing them into biology-based treatment approaches for patients with myeloid malignancies. He has focused on the clinical development of novel targeted therapies, promising combinations, and moving new immunotherapies into the clinic.

Clinically, Dr. Smith manages patients with myeloid malignancies, including acute and chronic myeloid leukemias, and myelodysplastic syndromes. He is recognized as a national leader in these areas and serves on the NCCN Guideline Panel for CML. He is a common guest editor for Journal of Clinical Oncology, Blood, Leukemia, Clinical Cancer Research, and other important journals for blood and marrow cancers. Dr. Smith also supports the Kimmel Cancer Center at Johns Hopkins by serving on the Fellowship Executive Committee and co-chairing one of the Scool of Medicine’s Institutional Review Board.

 JONATHAN WEBSTER, MD
 Instructor of Oncology
 Sidney Kimmel Comprehensive Cancer Center
 at Johns Hopkins
 Baltimore, MD

 


Jonathan Webster, MD is a 2011 graduate of the Stanford University School of Medicine. He then completed his residency training in internal medicine and fellowship training in medical oncology at Johns Hopkins University. He joined the faculty as an Instructor in the Division of Hematologic Malignancies within the Department of Oncology at Johns Hopkins in 2017.

As a member of the Leukemia Program, Dr. Webster treats patients with AML, ALL, and CML. His research focuses on the development of clinical trials incorporating novel agents and combinations in the treatment of ALL and AML. He is particularly interested in the potential application of immunotherapies to leukemia.
 

Jointly provided by Potomac Center for Medical Education and Rockpointe Oncology 
      

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Pfizer